A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)
Latest Information Update: 12 Aug 2021
At a glance
- Drugs Palopegteriparatide (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Ascendis Pharma Bone Diseases
- 06 Sep 2018 According to an Ascendis Pharma media release, design and results will be presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting
- 30 May 2018 According to the Ascendis Pharma media release, data from the complete multiple ascending dose cohorts were presented at the European Congress of Endocrinology.
- 30 May 2018 Status changed from recruiting to completed, according to the Ascendis Pharma media release.